Current and Emerging Targets in Immunotherapy for Osteosarcoma
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 2×
“The long-term survival rate for patients with localized osteosarcoma is about 65%, whereas it is less than 20% for patients with metastatic osteosarcomas [2, 4, 5].”
BackgroundAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“03) in patients with nonmetastatic osteosarcoma [24].”
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245 · cited 1×
“On the other hand, a randomized phase 3 trial showed that fiveyear event-free survival rates for 91 patients with metastatic osteosarcoma who received L-MTP-PE and those who did not were 42% and 26%, respectively [25].”
BackgroundLussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · cited 9×
“CTLA-4 and programmed death receptor1 (PD-1), the main inhibitory receptors expressed on T cells, have been considered as an important part in immune suppression induced by tumor cells, and these molecules are thought to be candidates as new therapeutic targets in various types of advanced malignancies [60].”
BackgroundInfluentialKleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157
Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., Liu, K., & Guo, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0560-1 · Cited by 151 · cited 1×
“Zheng investigated the efficacy of nivolumab in a mouse model of osteosarcoma and reported that nivolumab-treated mice had significantly fewermetastatic lung lesions, although nivolumab had no effect on primary tumor volume and growth [67].”
BackgroundMiwa, S., Nishida, H., Tanzawa, Y., Takeuchi, A., Hayashi, K., Yamamoto, N., Mizukoshi, E., Nakamoto, Y., Kaneko, S., & Tsuchiya, H. (2017) · Cancer · doi:10.1002/cncr.30606 · Cited by 95 · cited 2×
“Among the 35 patients who were assessed for clinical responses, one patient (3%) showed partial response, 6 patients (17%) showed stable disease, and 28 patients (80%) showed progression of the disease [43].”
BackgroundSelf-citationHimoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., et al. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0795-1 · Cited by 74
KAWANO, M., ITONAGA, I., IWASAKI, T., & TSUMURA, H. (2013) · Oncology Reports · doi:10.3892/or.2013.2224 · Cited by 51
Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma
KAWANO, M., TANAKA, K., ITONAGA, I., IWASAKI, T., MIYAZAKI, M., IKEDA, S., & TSUMURA, H. (2015) · Oncology Reports · doi:10.3892/or.2015.4161 · Cited by 38 · cited 1×
“Furthermore, they reported that combination treatment with tumor lysate-pulsed DCs and antiglucocorticoid-induced tumor necrosis factor receptor (antiGITR) antibodies enhanced the systemic immune response [42].”
BackgroundHe, Y.-T., Zhang, Q.-M., Kou, Q.-C., & Tang, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4714 · Cited by 22
Cited by
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Osteosarcoma: a review of current and future therapeutic approaches
Zhao, X., Wu, Q., Gong, X., Liu, J., & Ma, Y. (2021) · BioMedical Engineering OnLine · doi:10.1186/s12938-021-00860-0 · Cited by 312
Zhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Metadata
- Authors
- Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H.
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2019-01-01
- Volume
- 2019
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- OpenAlex
- W2907468621
- Cited by
- 122
- References
- 16
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.